Cryoport, Inc. (CYRX)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1124524 · fiscal year ends in Dec
Closing price $18.29 on 29 Oct 2026; 52-week range $7.72 to $18.64.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $926.1M
- Cash
- $269.3M
- Debt
- $186.8M
- Debt to equity
- 0.38
- Shares outstanding
- 50.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $176.2M | -$36.8M | $78.3M | $1.40 | -$25.0M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $156.8M | -$121.7M | -$114.8M | -$2.49 | -$33.6M | 10-K filed 7 Mar 2025 |
| FY2023 | 31 Dec 2023 | $168.7M | -$100.5M | -$99.6M | -$2.21 | -$39.5M | 10-K filed 13 Mar 2024 |
| FY2022 | 31 Dec 2022 | $237.3M | -$31.9M | -$37.3M | -$0.93 | -$24.0M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $222.6M | -$17.8M | -$275.5M | -$6.19 | -$15.8M | 10-K filed 28 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $49.0M | -$8.3M | -$0.20 |
| Q1 FY2026 | 31 Mar 2026 | $47.8M | -$10.5M | -$0.25 |
| Q4 FY2025 | 31 Dec 2025 | – | – | – |
| Q3 FY2025 | 30 Sep 2025 | $44.2M | -$6.9M | -$0.18 |
| Q2 FY2025 | 30 Jun 2025 | $45.5M | $105.2M | $2.05 |
| Q1 FY2025 | 31 Mar 2025 | $41.0M | -$12.0M | -$0.28 |
| Q4 FY2024 | 31 Dec 2024 | $59.5M | -$18.7M | -$0.42 |
| Q3 FY2024 | 30 Sep 2024 | $38.3M | $805.0K | -$0.02 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Life Sciences Services | $102.1M | 57.4% |
| Life Sciences Products | $75.8M | 42.6% |
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product | $79.7M | 45.2% |
| BioLogistics Solutions | $78.1M | 44.4% |
| BioStorage/BioServices | $18.4M | 10.4% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Americas | $131.3M | 74.5% |
| EMEA | $25.1M | 14.3% |
| Asia Pacific | $19.8M | 11.2% |
Company events
The newest 8-K filings of 208 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 9 Jun 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 4 May 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 13 Jun 2025 | 8-K | Deal completed, Investor update | 2.01, 7.01, 9.01 |
| 10 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 7 May 2025 | 8-K | Results | 2.02, 9.01 |
| 31 Mar 2025 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 4 Mar 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Nov 2024 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 565 held.
| Filed | Form | Period |
|---|---|---|
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 22 Jun 2026 | S-8 | – |
| 22 Jun 2026 | 15-12G | – |
| 9 Jun 2026 | 8-K | 5 Jun 2026 |
| 29 May 2026 | SD | – |
| 5 May 2026 | 10-Q | 31 Mar 2026 |
| 4 May 2026 | 8-K | 4 May 2026 |
| 22 Apr 2026 | ARS | 31 Dec 2025 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 5 Jun 2026 |
| 5 Mar 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 11 Aug 2026 | Shelton Jerrell, President, CEO | Sale under a trading plan | 28,800 | $14.91 | $429.4K | 1,201,814 | 11 Aug 2026 |
| 11 Jun 2026 | Zecchini Edward J, Chief Digital and Tech Officer | Sale outside a trading plan | 33,600 | $14.47 | $486.2K | 109,719 | 12 Jun 2026 |
| 10 Jun 2026 | Zecchini Edward J, Chief Digital and Tech Officer | Sale outside a trading plan | 1,400 | $15.23 | $21.3K | 109,719 | 12 Jun 2026 |
| 8 Jun 2026 | Mandalam Ramkumar, Director | Sale outside a trading plan | 23,214 | $15.44 | $358.5K | 67,894 | 8 Jun 2026 |
| 4 Jun 2026 | Stefanovich Robert, Chief Financial Officer | Sale outside a trading plan | 169,427 | $16.27 | $2.8M | 109,850 | 8 Jun 2026 |
| 23 Mar 2026 | Stefanovich Robert, Chief Financial Officer | Sale outside a trading plan | 1,094 | $8.18 | $8.9K | 279,277 | 25 Mar 2026 |
| 23 Mar 2026 | Shelton Jerrell, President, CEO | Sale outside a trading plan | 2,894 | $8.18 | $23.7K | 1,051,607 | 25 Mar 2026 |
| 23 Mar 2026 | Sawicki Mark W, Chief Scientific Officer | Sale outside a trading plan | 1,341 | $8.18 | $11.0K | 102,356 | 25 Mar 2026 |
| 16 Mar 2026 | Zecchini Edward J, See Remarks | Sale outside a trading plan | 2,014 | $8.00 | $16.1K | 109,719 | 17 Mar 2026 |
| 16 Mar 2026 | Shelton Jerrell, President, CEO | Sale outside a trading plan | 7,918 | $8.00 | $63.3K | 1,054,501 | 17 Mar 2026 |
| 16 Mar 2026 | Sawicki Mark W, Chief Scientific Officer | Sale outside a trading plan | 3,235 | $8.00 | $25.9K | 103,697 | 17 Mar 2026 |
| 16 Mar 2026 | Stefanovich Robert, Chief Financial Officer | Sale outside a trading plan | 2,743 | $8.00 | $21.9K | 280,371 | 16 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 11 Aug 2026 | JERRELL W SHELTON, Director, Officer | 28,800 | $426.8K | 11 Aug 2026 |
| 11 Jun 2026 | EDWARD ZECCHINI, Officer | 33,600 | $486.2K | 11 Jun 2026 |
| 10 Jun 2026 | EDWARD ZECCHINI, Officer | 1,400 | $21.3K | 10 Jun 2026 |
| 8 Jun 2026 | RAMKUMAR MANDALAM, Director | 23,214 | $358.5K | 8 Jun 2026 |
| 3 Jun 2026 | STEFANOVICH ROBERT, Officer | 169,427 | $2.8M | 4 Jun 2026 |
| 12 Mar 2026 | ROBERT S. STEFANOVICH, Officer | 38,700 | $300.4K | 12 Mar 2026 |
| 10 Dec 2025 | RAMKUMAR MANDALAM, Director | 11,570 | $115.5K | 10 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Cadian Capital Management, LP | 13G amended | 5.8% | 2.9M |
| 13 Aug 2026 | Morgan Stanley | 13G amended | 4.5% | 2.2M |
| 29 Jul 2026 | Integrated Core Strategies (US) LLC | 13G amended | 3.4% | 1.7M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Brown Capital Management, LLC | 13G amended | 2.2% | 1.1M |
| 5 Feb 2026 | Integrated Core Strategies (US) LLC | 13G amended | 6.5% | 3.2M |
| 12 Nov 2025 | Brown Capital Management, LLC | 13G amended | 5.24% | 2.6M |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 15 Sep 2023 | Josh Gottheimer (NJ05) | Sale | $1,001 - $15,000 | 15 Oct 2023 |
| 28 Feb 2022 | Donald Sternoff Beyer (VA08) | Sale | $1,001 - $15,000 | 3 Mar 2022 |
| 31 Jan 2022 | Donald Sternoff Beyer (VA08) | Sale | $1,001 - $15,000 | 1 Feb 2022 |
| 13 Jan 2022 | Donald Sternoff Beyer (VA08) | Sale | $1,001 - $15,000 | 1 Feb 2022 |
| 14 Jan 2022 | Donald Sternoff Beyer (VA08) | Sale | $1,001 - $15,000 | 1 Feb 2022 |
| 21 Sep 2021 | Donald Sternoff Honorable Beyer (VA08) | Sale | $1,001 - $15,000 | 1 Oct 2021 |
| 24 Nov 2020 | Gilbert Cisneros (CA39) | Sale (partial) | $1,001 - $15,000 | 15 Dec 2020 |
| 13 Nov 2020 | Josh Gottheimer (NJ05) | Sale (partial) | $1,001 - $15,000 | 9 Dec 2020 |
| 2 Nov 2020 | Donald Sternoff Beyer (VA08) | Purchase | $1,001 - $15,000 | 1 Dec 2020 |
| 17 Nov 2020 | Donald Sternoff Beyer (VA08) | Purchase | $1,001 - $15,000 | 1 Dec 2020 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.5M | +7.2% | 3.06 |
| 30 Sep 2026 | 2.4M | -15.21% | 3.38 |
| 15 Sep 2026 | 2.8M | +2.68% | 5.83 |
| 31 Aug 2026 | 2.7M | +7.88% | 4.85 |
| 14 Aug 2026 | 2.5M | +0.64% | 4.65 |
| 31 Jul 2026 | 2.5M | -0.84% | 4.04 |
| 15 Jul 2026 | 2.5M | +15.72% | 3.68 |
| 30 Jun 2026 | 2.2M | -0.87% | 2.57 |
Funds that hold it
From each fund's latest Form 13F.
199 funds held it at 30 Jun 2026: 96 added and 49 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 4,218,434 | $66.2M | +237,536 |
| Cadian Capital Management, LP | 2,920,681 | $45.9M | -1,855,662 |
| First Eagle Investment Management, LLC | 2,542,848 | $39.9M | – |
| Assenagon Asset Management S.A. | 2,304,622 | $36.2M | – |
| Morgan Stanley | 2,276,741 | $35.7M | -2,299,989 |
| Vanguard Capital Management LLC | 2,151,943 | $33.8M | +33,087 |
| Millennium Management LLC | 1,724,726 | $27.1M | -1,245,738 |
| Fred Alger Management, LLC | 1,545,293 | $24.3M | -154,086 |
| Geode Capital Management, LLC | 1,312,370 | $20.6M | +64,235 |
| Mak Capital One LLC | 1,277,359 | $20.1M | -145,906 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B